Recent news
November 2010
TB Alliance launches trial of new drug regimen
November 10, 2010 -- The Global Alliance for TB Drug Development (TB Alliance) recently announced the launch of a Phase I clinical trial to test a novel tuberculosis (TB) regimen that aims to speed new treatments to patients. The three-drug combination has demonstrated promise to treat both drug-sensitive and multidrug-resistant TB, and shorten and simplify treatment worldwide. “We need more than a new drug to eradicate TB—we need entirely new regimens of TB drugs," said Mel Spigelman, president and chief executive officer of the TB Alliance. He added, "The potential to offer a single regimen to treat both drug-sensitive and multidrug-resistant TB represents a monumental advance in the treatment of patients worldwide, and a tremendous step toward simplifying the delivery of TB treatment globally." The research is supported by the Critical Path to TB Drug Regimens (CPTR), an initiative established to tackle the regulatory and other challenges associated with TB drug development. CPTR was founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance. See the link below for further details.
